LifeMD Inc (LFMD)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $106.09M
Last updated: Nov 17, 2026 at 11:04 AM ET
LifeMD Inc (LFMD) Earnings: Report Dates and Results
LifeMD (LFMD) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, LifeMD reported EPS of -$0.11, above the -$0.14 estimate. It beat the EPS estimate in 2 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
LFMD has an expected report date of Mar 8, 2027.
LFMD Earnings Call
The latest LFMD earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 25 quarters below that had an estimate, LFMD beat 13, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $44.63M, down 6.5% from $47.73M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.11 | -$0.14 | N/A | +21.43% | Beat | N/A | 2 | 0 up, 1 down | Nov 12, 2026 | $44.63M |
| Jun 30, 2026 | -$0.15 | -$0.04 | -$0.09 - $0.00 | -275.00% | Miss | N/A | 2 | 0 up, 1 down | Aug 5, 2026 | $47.28M |
| Mar 31, 2026 | -$0.15 | -$0.12 | -$0.13 - -$0.12 | -29.91% | Miss | -605.3% | 2 | 0 up, 1 down | May 6, 2026 | $50.16M |
| Dec 31, 2025 | $0.06 | $0.09 | -$0.08 - $0.15 | -33.33% | Miss | -71.4% | 3 | 0 up, 1 down | Mar 9, 2026 | $46.87M |
| Sep 30, 2025 | -$0.08 | $0.05 | -$0.04 - $0.13 | -260.00% | Miss | -188.9% | 2 | 0 up, 1 down | Nov 17, 2025 | $47.73M |
| Jun 30, 2025 | -$0.01 | $0.18 | $0.18 - $0.18 | -105.56% | Miss | -116.7% | 1 | 1 up, 0 down | Aug 4, 2025 | $49.02M |
| Mar 31, 2025 | $0.03 | $0.14 | $0.14 - $0.14 | -78.57% | Miss | +200.0% | 1 | 0 up, 1 down | May 6, 2025 | $50.89M |
| Dec 31, 2024 | $0.21 | $0.14 | $0.14 - $0.14 | +50.00% | Beat | N/A | 1 | 0 up, 1 down | Mar 10, 2025 | $64.25M |
| Sep 30, 2024 | $0.09 | $0.07 | N/A | +28.57% | Beat | +12.5% | 6 | 0 up, 0 down | Nov 7, 2024 | $53.27M |
| Jun 30, 2024 | $0.06 | $0.04 | N/A | +50.00% | Beat | +20.0% | 4 | 0 up, 0 down | Aug 7, 2024 | $50.66M |
| Mar 31, 2024 | $0.01 | -$0.01 | N/A | +200.00% | Beat | N/A | 5 | 0 up, 0 down | May 8, 2024 | $44.14M |
| Dec 31, 2023 | -$0.12 | -$0.14 | -$0.16 - -$0.12 | +14.29% | Beat | N/A | 5 | 0 up, 0 down | Mar 11, 2024 | $44.86M |
| Sep 30, 2023 | $0.08 | $0.03 | N/A | +166.67% | Beat | N/A | 4 | 0 up, 0 down | Nov 8, 2023 | $38.61M |
| Jun 30, 2023 | $0.05 | $0.03 | N/A | +66.67% | Beat | N/A | 3 | 0 up, 0 down | Aug 9, 2023 | $35.95M |
| Mar 31, 2023 | -$0.15 | -$0.16 | -$0.16 - -$0.16 | +6.25% | Beat | N/A | 1 | 1 up, 0 down | May 12, 2023 | $33.13M |
| Dec 31, 2022 | -$0.40 | -$0.18 | -$0.18 - -$0.18 | -122.22% | Miss | N/A | 1 | 0 up, 0 down | Mar 22, 2023 | $28.12M |
| Sep 30, 2022 | -$0.03 | -$0.12 | N/A | +75.00% | Beat | N/A | 2 | 0 up, 0 down | Nov 10, 2022 | $31.41M |
| Jun 30, 2022 | -$0.22 | -$0.23 | N/A | +4.35% | Beat | N/A | 2 | 0 up, 0 down | Aug 11, 2022 | $30.46M |
| Mar 31, 2022 | -$0.46 | -$0.36 | -$0.41 - -$0.32 | -27.78% | Miss | N/A | 2 | 0 up, 1 down | May 13, 2022 | $29.04M |
| Dec 31, 2021 | -$0.29 | -$0.39 | -$0.49 - -$0.36 | +25.64% | Beat | N/A | 2 | 0 up, 0 down | Mar 7, 2022 | $27.42M |
| Sep 30, 2021 | -$0.36 | -$0.49 | N/A | +26.53% | Beat | N/A | 2 | N/A | Nov 10, 2021 | $24.95M |
| Jun 30, 2021 | -$0.51 | -$0.45 | N/A | -13.33% | Miss | N/A | 2 | N/A | Aug 12, 2021 | $22.31M |
| Mar 31, 2021 | -$0.48 | -$0.44 | -$1.03 - -$0.32 | -9.09% | Miss | N/A | 2 | N/A | May 13, 2021 | $18.20M |
| Dec 31, 2020 | -$2.56 | -$0.24 | -$0.27 - -$0.22 | -966.67% | Miss | N/A | 2 | N/A | Mar 29, 2021 | $12.89M |
| Sep 30, 2020 | -$1.03 | -$1.03 | N/A | 0.00% | In line | N/A | N/A | N/A | Nov 16, 2020 | $11.01M |
| Jun 30, 2020 | -$2.54 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2020 | $9.09M |
| Mar 31, 2020 | -$0.22 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 19, 2020 | $4.30M |
| Dec 31, 2019 | -$0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 30, 2020 | $3.94M |
| Sep 30, 2019 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2019 | $3.13M |
| Jun 30, 2019 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 14, 2019 | $2.70M |
| Mar 31, 2019 | -$0.07 | N/A | N/A | N/A | N/A | -204.6% | N/A | N/A | May 15, 2019 | $2.70M |
| Dec 31, 2018 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 29, 2019 | $2.18M |
| Sep 30, 2018 | -$0.06 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2018 | $2.50M |
| Jun 30, 2018 | -$0.07 | N/A | N/A | N/A | N/A | -190.1% | N/A | N/A | Aug 17, 2018 | $2.04M |
| Mar 31, 2018 | $0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 2, 2018 | $1.61M |
| Dec 31, 2017 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2017 | $802107 |
| Sep 30, 2017 | -$0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 14, 2017 | $2.05M |
| Jun 30, 2017 | $0.08 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Jul 7, 2017 | $660087 |
| Mar 31, 2017 | -$0.14 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2017 | $167899 |
| Dec 31, 2016 | -$0.09 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Dec 31, 2016 | $985900 |
Annual EPS
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | Not reported | N/A |
| Dec 31, 2024 | $0.37 | N/A |
| Dec 31, 2023 | -$0.14 | N/A |
| Dec 31, 2022 | -$1.11 | N/A |
| Dec 31, 2021 | -$1.64 | N/A |
| Dec 31, 2020 | -$6.35 | N/A |
| Dec 31, 2019 | -$0.32 | N/A |
| Dec 31, 2018 | -$0.14 | N/A |
| Dec 31, 2017 | -$0.16 | N/A |
| Dec 31, 2016 | -$0.16 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,500 words across 7 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,520 | 7 | |
| 2026Q2 | Jun 30, 2026 | 7,135 | 7 | |
| 2026Q1 | Mar 31, 2026 | 5,286 | 9 | |
| 2025Q4 | Dec 31, 2025 | 4,662 | 8 | |
| 2025Q3 | Sep 30, 2025 | 5,992 | 8 | |
| 2025Q2 | Jun 30, 2025 | 4,718 | 9 | |
| 2025Q1 | Mar 31, 2025 | 4,318 | 9 | |
| 2024Q3 | Sep 30, 2024 | 5,736 | 8 |
2026Q3 Earnings Call
Opening remarks
Justin Schreiber Chairman and CEO Thank you, operator, and good afternoon, everyone. Earlier this afternoon, we issued our third quarter release and filed our 10-Q. Let me start with the numbers. Revenue was $44.6 million, below the range we guided to. Adjusted EBITDA was slightly negative within our guidance range and a $3.1 million improvement over the second quarter. We are also resetting our outlook for the fourth quarter and the full year. Last quarter, I told you we expected to exit the year at a $250 million revenue run rate. We won't. We now expect to exit at roughly a $200 million revenue run rate. There were three things that drove the shortfall. First, our guidance assumed our branded GLP-1 fulfillment program would begin earlier in the quarter. Finalizing and implementing those arrangements took longer than we planned, so less of that revenue landed in the third quarter. This was a timing issue, not a demand issue. Arrangements with manufacturers are now in place and the program is ramping, as I'll discuss in a moment. Second, we took a conservative approach to new patient acquisition. We cut marketing spend by almost one-third quarter-over-quarter, while we improved our technology platform and patient experience to drive better unit economics and patient retention. We also chose longer patient subscription commitments over upfront revenue. Those choices cost us revenue this quarter. Third, and this is related to the second, some of the patient cohorts we brought on earlier this year didn't perform the way we expected. This is a big part of why we pulled back. We made pricing and plan changes to address that, and rather than scale spend before we knew those changes were working, we chose to hold back until our new cohorts proved out. The early results are encouraging, and I'll come back to those shortly. The most important takeaway for our shareholders is that despite some continued softness in the business, we are in a strong liquidity position and I believe we have an amazing year of high-quality growth ahead of us. I'm going to keep the rest of my remarks short because the message is simple. It comes down to five things. First, we are more confident than ever in our decision to build LifeMD's weight management offering around branded GLP-1s. In the last 30 days, we completed arrangements with both Eli Lilly and Novo Nordisk that enable us to integrate self-pay GLP-1 medications directly into our pharmacy operations, further expanding access to these products by removing friction from the patient experience. Second, our enterprise business is off to a strong start.
Frequently Asked Questions About LFMD
When is LifeMD's next earnings date?
LifeMD's next earnings report is expected for Mar 8, 2027.
Did LFMD beat earnings estimates last quarter?
Yes. LifeMD reported EPS of -$0.11 for the quarter ended Sep 30, 2026, above the -$0.14 estimate, a 21.43% surprise.
What EPS do analysts expect from LFMD next quarter?
The consensus EPS estimate for LifeMD for the quarter ending Dec 31, 2026 is -$0.09 from 10 analysts, with estimates from -$0.20 to $0.06.
How often does LFMD beat earnings estimates?
LifeMD beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -88.87%.
LFMD pages: Overview, Earnings, Forecast, Financials, Competitors